ArticleFrontiers in pharmacology2020
Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Exploring the Anticancer Properties of 1,2,3-Triazole-Substituted Andrographolide Derivatives.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Nitrogen-containing andrographolide derivatives with multidrug resistance reversal effects in cancer cells.RSC medicinal chemistry · 2024Article
- Transcription factor E2F3 activates CDC25B to regulate DNA damage and promote mitoxantrone resistance in stomach adenocarcinoma.Molecular biology reports · 2024Article
- LC-ESI QToF MS Non-Targeted Screening of Latex Extracts ofPlants (Basel, Switzerland) · 2023Article
- Lycorine Carbamate Derivatives for Reversing P-glycoprotein-Mediated Multidrug Resistance in Human Colon Adenocarcinoma Cells.International journal of molecular sciences · 2023Article
- Amaryllidaceae-Type Alkaloids fromMolecules (Basel, Switzerland) · 2022Article
- Pharmacological Potential of Lathyrane-Type Diterpenoids from Phytochemical Sources.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Research Progress on Natural Diterpenoids in Reversing Multidrug Resistance.Frontiers in pharmacology · 2022Review
- Overcoming Multidrug Resistance: Flavonoid and Terpenoid Nitrogen-Containing Derivatives as ABC Transporter Modulators.Molecules (Basel, Switzerland) · 2020Review
- Zoopharmacology: A Way to Discover New Cancer Treatments.Biomolecules · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug resistance (MDR) has been regarded as one of the major hurdles for the successful outcome of cancer chemotherapy. The collateral sensitivity (CS) effect is one the most auspicious anti-MDR strategies. Epoxylathyrane derivatives PURPOSE: The main goal was to develop lathyrane-type macrocyclic diterpenes with improved MDR-modifying activity, by targeting more than one anti-MDR mechanism. STUDY DESIGN/
methodsIn this study, the potential CS effect of compounds
resultsThe compounds were more effective against the resistant gastric cell lines, being the CS effect more significant in EPG85-257RDB cells. Taking together the IC
conclusionsThis study reinforces the importance of lathyrane-type diterpenes as lead molecules for the research of MDR-modifying agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.